Drugs and devices intended for women have a controversial history that may hamper pharmaceutical, biologic, and device research specific to women.
Departments of Health Policy and Management and Obstetrics and Gynecology, Louisiana State University, Schools of Public Health and Medicine, New Orleans, Louisiana; the Jacobs Institute of Women's Health, the Department of Health Policy, School of Public Health and Health Services, George Washington University, and Cavarocchi|Ruscio|Dennis Associates, LLC, Washington, DC.
Corresponding author: Rebekah E. Gee, MD, MPH, 2020 Gravier Street, New Orleans, LA 70112; e-mail: firstname.lastname@example.org.
The authors thank the members of the Health Policy Committee of the Society for Maternal-Fetal Medicine (SMFM) for their significant contributions to this manuscript. Members of the SMFM Health Policy Committee with editing contributions are: Joanne Armstrong, Suneet P. Chauhan, Judette Louis, George R. Saade, and Sindhu Srinivas.
Financial Disclosure The authors did not report any potential conflicts of interest.